4-(2-methoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester | 479630-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-methoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(3-methoxy-3-oxopropanoyl)piperidine- 1-carboxylate；tert-butyl 4-(3-methoxy-3-oxopropanoyl)piperidine-1-carboxylate；1-Boc-beta-oxo-4-piperidinepropanoic acid methyl ester
• CAS: 479630-02-9
• 化学式: C₁₄H₂₃NO₅
• 分子量: 285.34
• InChiKey: WMAWVWUIHBXMPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-methoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以15.8 g的产率得到4-(5-oxo-4,5-dihydro-1H-pyrazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Integrating Fragment Assembly and Biophysical Methods in the Chemical Advancement of Small-Molecule Antagonists of IL-2:  An Approach for Inhibiting Protein−Protein Interactions

  摘要：

  Fragment assembly has shown promise for discovering small-molecule antagonists for difficult targets, including protein-protein interactions. Here, we describe a process for identifying a 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2 receptor (IL-2Ralpha) interaction. By use of fragment-based approaches, a compound with millimolar affinity was evolved to a hit series with low micromolar activity, and these compounds were optimized into a lead series with nanomolar affinity. Fragment assembly was useful not only for hit identification, but also for lead optimization. Throughout the discovery process, biophysical methods and structural biology demonstrated that compounds bound reversibly to IL-2 at the IL-2 receptor binding site.

  DOI：

  10.1021/jm049967u
• 作为产物：
  描述：

  1-Boc-4-哌啶甲酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-(2-methoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS AS TGR5 AGONISTS
  [FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'AGONISTES DE TGR5

  摘要：

  该发明提供了公式(I)的化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与TGR5相关的疾病或紊乱的方法。

  公开号：

  WO2012082947A1

文献信息

• Synthesis and Characterization of Novel Methyl (3)5-(N-Boc-piperidinyl)-1H-pyrazole-4-carboxylates
  作者：Gita Matulevičiūtė、Eglė Arbačiauskienė、Neringa Kleizienė、Vilija Kederienė、Greta Ragaitė、Miglė Dagilienė、Aurimas Bieliauskas、Vaida Milišiūnaitė、Frank A. Sløk、Algirdas Šačkus

  DOI：10.3390/molecules26133808

  日期：——

  Series of methyl 3- and 5-(N-Boc-piperidinyl)-1H-pyrazole-4-carboxylates were developed and regioselectively synthesized as novel heterocyclic amino acids in their N-Boc protected ester form for achiral and chiral building blocks. In the first stage of the synthesis, piperidine-4-carboxylic and (R)- and (S)-piperidine-3-carboxylic acids were converted to the corresponding β-keto esters, which were

  开发了一系列 3- 和 5-( N -Boc-哌啶基)-1 H-吡唑-4-羧酸甲酯，并将其作为新型杂环氨基酸以N- Boc 保护的酯形式合成，用于非手性和手性结构单元。在合成的第一阶段，哌啶-4-羧酸和（R）-和（S）-哌啶-3-羧酸转化为相应的β-酮酯，然后用N , N-二甲基甲酰胺二甲基甲酰胺处理。缩醛。随后β-烯胺二酮与各种N-单取代肼反应得到目标5-( N - Boc-哌啶基)-1 H以-吡唑-4-羧酸盐为主要产物，由水合肼制备的互变异构的NH-吡唑进一步用卤代烷进行N-烷基化，得到3-( N -Boc-哌啶基) -1H-吡唑-4-羧酸盐。新型杂环化合物的结构已通过1 H-、13 C- 和15 N-NMR 光谱和 HRMS 研究证实。
• Regioselective synthesis of methyl 5-(<i>N</i>-Boc-cycloaminyl)-1,2-oxazole-4-carboxylates as new amino acid-like building blocks
  作者：Jolita Bruzgulienė、Greta Račkauskienė、Aurimas Bieliauskas、Vaida Milišiūnaitė、Miglė Dagilienė、Gita Matulevičiūtė、Vytas Martynaitis、Sonata Krikštolaitytė、Frank A Sløk、Algirdas Šačkus

  DOI：10.3762/bjoc.18.11

  日期：——

  A convenient and efficient synthesis of novel achiral and chiral heterocyclic amino acid-like building blocks was developed. Regioisomeric methyl 5-(N-Boc-cycloaminyl)-1,2-oxazole-4-carboxylates were prepared by the reaction of β-enamino ketoesters (including azetidine, pyrrolidine or piperidine enamines) with hydroxylamine hydrochloride. Unambiguous structural assignments were based on chiral HPLC

  开发了一种方便有效的合成新型非手性和手性杂环氨基酸类结构单元的方法。通过β-烯胺酮酯（包括氮杂环丁烷、吡咯烷或哌啶烯胺）与盐酸羟胺反应制备区域异构的5-( N -Boc-环氨基)-1,2-恶唑-4-甲酸甲酯。明确的结构归属基于手性 HPLC 分析、 1 H、 13 C 和15 N NMR 光谱、HRMS 和单晶 X 射线衍射数据。
• [EN] HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE SOS1
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2022156792A1

  公开（公告）日：2022-07-28

  This disclosure relates to heterocyclics as inhibitors of SOS1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that are useful for treatment of SOS1 mediated diseases and conditions such as cancer.

  本公开涉及杂环化合物作为SOS1抑制剂，特别涉及式I化合物或其药学上可接受的盐，以及包含该化合物的制药组合物，用于治疗SOS1介导的疾病和状况，如癌症。
• Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11053235B2

  公开（公告）日：2021-07-06

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病，特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物，以及其在制药或医疗方面的应用。
• DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：EP3814326A1

  公开（公告）日：2021-05-05